Trials / Conditions / Chronic Heart Failure With Reduced Ejection Fraction

Chronic Heart Failure With Reduced Ejection Fraction

20 registered clinical trials studyying Chronic Heart Failure With Reduced Ejection Fraction — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Prospective, Single-center, Randomized Controlled Clinical Study Evaluating the Efficacy and Safety of Hyper NCT07311109	Fujian Medical University	N/A
Active Not Recruiting	An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With NCT06632483	Bayer	—
Completed	An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate NCT06697353	Bayer	—
Completed	An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Tre NCT06486844	Bayer	—
Completed	A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart NCT06195930	Bayer	Phase 2
Completed	An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic NCT06363110	Bayer	—
Recruiting	An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure W NCT06148935	Bayer	—
Completed	The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People Wit NCT05974189	Bayer	—
Completed	An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in NCT05728502	Bayer	—
Completed	A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian P NCT05658458	Bayer	Phase 4
Recruiting	S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction NCT05553886	Shenzhen People's Hospital	Phase 3
Completed	A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFr NCT05093933	Merck Sharp & Dohme LLC	Phase 3
Completed	Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure NCT04983043	Tasly Pharmaceutical Group Co., Ltd	Phase 2
Completed	A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Fa NCT04836182	Ionis Pharmaceuticals, Inc.	Phase 2
Completed	A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction NCT04840914	Eli Lilly and Company	Phase 1
Withdrawn	Omecamtiv Mecarbil Post-trial Access Study NCT04464525	Cytokinetics	Phase 3
Completed	randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Fail NCT02900378	Novartis Pharmaceuticals	Phase 3
Completed	A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) NCT02861534	Merck Sharp & Dohme LLC	Phase 3
Completed	Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fr NCT02768298	Novartis Pharmaceuticals	Phase 4
Completed	Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Frac NCT02226120	Novartis Pharmaceuticals	Phase 3